Market research
LPTX Leap Therapeutics Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 116M
- P/E ratio
- Not available
- Analyst target
- 3
- Dividend yield
- Not available
- Beta
- 0.09
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US52187K2006
- Market cap
- 116M
- P/E ratio
- Not available
- Analyst target
- 3
- Dividend yield
- Not available
- Beta
- 0.09
About
About Leap Therapeutics Inc
Cypherpunk Technologies Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial. It has an option and license agreement with Adimab, LLC and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as Leap Therapeutics, Inc. and changed its name to Cypherpunk Technologies Inc. in November 2025. The company was incorporated in 2011 and is based in Cambridge, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the LPTX discussion.
5 years, 4 months ago
Leap Therapeutics, Inc is currently in a long term downtrend where the price is trading 21.6% below its 200 day moving average.
From a valuation standpoint, the stock is 94.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 75.1.
Leap Therapeutics, Inc's total revenue rose by inf% to $375K since the same quarter in the previous year.
Its net income has increased by 16.1% to $-7M since the same quarter in the previous year.
Finally, its free cash flow grew by 0.1% to $-6M since the same quarter in the previous year.
Based on the above factors, Leap Therapeutics, Inc gets an overall score of 4/5.